Seeking Alpha

Progenics completes enrollment in mCRPC trial

  • Progenics Pharmaceuticals (PGNX +2.4%) completes enrollment in a Phase 2 study of PSMA ADC in metastatic castrate resistant prostate cancer.
  • The enrolled patients are chemotherapy experienced.
  • The company is also enrolling chemotherapy naive patients in a second cohort.
  • Top-line data from the chemotherapy experienced cohort is expected in January. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs